| 2014 |
Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson‐Hughes B. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. November 2014;29(11):2520-2526. |
84 |
83 |
| 2017 |
Khosla S, Cauley JA, Compston J, Kiel DP, Rosen C, Saag KG, Shane E. Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res. March 2017;32(3):424-430. |
16 |
13 |
| 2020 |
Conley RB, Adib G, Adler RA, Åkesson KE, Alexander IM, Amenta KC, Blank RD, Brox WT, Carmody EE, Chapman‐Novakofski K, Clarke BL, Cody KM, Cooper C, Crandall CJ, Dirschl DR, Eagen TJ, Elderkin AL, Fujita M, Greenspan SL, Halbout P, Hochberg MC, Javaid M, Jeray KJ, Kearns AE, King T, Koinis TF, Koontz JS, Kužma M, Lindsey C, Lorentzon M, Lyritis GP, Michaud LB, Miciano A, Morin SN, Mujahid N, Napoli N, Olenginski TP, Puzas JE, Rizou S, Rosen CJ, Saag K, Thompson E, Tosi LL, Tracer H, Khosla S, Kiel DP. Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. J Bone Miner Res. January 2020;35(1):36-52. |
12 |
9 |
| 2020 |
Adami G, Jaleel A, Curtis JR, Delzell E, Chen R, Yun H, Daigle S, Arora T, Danila MI, Wright NC, Cadarette SM, Mudano A, Foster J, Saag KG. Temporal trends and factors associated with bisphosphonate discontinuation and restart. J Bone Miner Res. March 2020;35(3):478-487. |
0 |
0 |
| 2020 |
Saag KG, Curtis JR, Reid IR. Reply to serious adverse events with romosozumab use in Japanese patients: need for clear formulation of contraindications worldwide. J Bone Miner Res. May 2020;35(5):996-997. |
1 |
1 |
| 2022 |
Geusens P, Bevers MSAM, van Rietbergen B, Messina OD, Lespessailles E, Oliveri B, Chapurlat R, Engelke K, Chines A, Huang S, Saag KG, van den Bergh JP. Effect of denosumab compared with risedronate on bone strength in patients initiating or continuing glucocorticoid treatment. J Bone Miner Res. June 2022;37(6):1136-1146. |
0 |
0 |
| 2022 |
Czerwinski E, Cardona J, Plebanski R, Recknor C, Vokes T, Saag KG, Binkley N, Lewiecki EM, Adachi J, Knychas D, Kendler D, Orwoll E, Chen Y, Pearman L, Li YH, Mitlak B. The efficacy and safety of abaloparatide-sc in men with osteoporosis: a randomized clinical trial. J Bone Miner Res. December 2022;37(12):2435-2442. |
0 |
0 |
| 2017 |
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. NEJM. October 12, 2017;377(15):1417-1427. |
76 |
63 |
| 2020 |
Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster J-Y. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. January 2020;31(1):1-12. |
12 |
7 |
| 2020 |
Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster JY. Correction to: algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. April 2020;31(4):797-798. |
0 |
0 |
| 2020 |
Adami G, Saag KG, Mudano AS, Rahn EJ, Wright NC, Outman RC, Greenspan SL, LaCroix AZ, Nieves JW, Silverman SL, Siris ES, Watts NB, Miller MJ, Ladores S, Curtis JR, Danila MI. Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment. Osteoporos Int. July 2020;31(7):1283-1290. |
0 |
0 |
| 2021 |
Lane NE, Saag K, O’Neill TJ, Manion M, Shah R, Klause U, Eastell R. Correction to: real-world bone turnover marker use: impact on treatment decisions and fracture. Osteoporos Int. March 2021;32(3):609-609. |
0 |
0 |
| 2021 |
Lane NE, Saag K, O’Neill TJ, Manion M, Shah R, Klause U, Eastell R. Real-world bone turnover marker use: impact on treatment decisions and fracture [published correction appears in Osteoporos Int. March 2021;32(3):609-609]. Osteoporos Int. May 2021;32(5):831-840. |
0 |
0 |